Relationship between The Expression of DNA Repair Enzyme : ERCC1 (excision repair cross-complementing l) and Resistance to CDDP (cis-dichlorodiammineplatinum(II) ) in Human Esophageal Squamous Cell Carcinoma Cell Lines.

Chemotherapy using CDDP has demonstrated efficacy in esophageal cancer. The activity of ERCC1 is well correlated with resistance to CDDP in ovarian cancer and hematopoietic malignancies. Studies in vitro were therefore undertaken to investigate the relationship between the expression of ERCC1 and resistance to CDDP in six human esophageal cancer cell lines (ECC) (YES-1, -2, -3, -4, -5, _6) using RT-PCR, Western blot analysis and immunostaining for ERCC1 expression and MTT assay or sensitivity against CDDP. IC_50 of CDDP in YES-1, -2, -3, -4, -5, _6 cells were > 20, 5.0 ± 0,80, 6.0 ± 0.50, 0.65 ± 0.14, > 20, and > 20 ng/ml, respectively. YES-4 cells showed high sensitivity to CDDP compared with 5 other ECCs. The expression of ERCC1 mRNA and its protein in YES-4 and -5 significantly decreased compared with 4 other ECCs. The sensitivity for CDDP in ECCs were correlated with the ERCC1 expression, except for YES-5. These results suggest that ERCC1 may contribute to resistance to CDDP in esophageal cancer.

ERCC1 (excision repair cross-complementing 1)

DNA修復

シスプラチン

薬剤耐性

食道癌